Ultragenyx Pharmaceutical RARE EMEA — Revenue
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ultragenyx Pharmaceutical's emea — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ultragenyx Pharmaceutical's EMEA — revenue?
- Ultragenyx Pharmaceutical (RARE) reported EMEA — revenue of $31M in Q1 2026.
- How has Ultragenyx Pharmaceutical's EMEA — revenue changed year-over-year?
- Ultragenyx Pharmaceutical's EMEA — revenue increased by 34.8% year-over-year, from $23M to $31M.
- What is the long-term trend for Ultragenyx Pharmaceutical's EMEA — revenue?
- Over 3 years (2022 to 2025), Ultragenyx Pharmaceutical's EMEA — revenue has grown at a 43.6% compound annual growth rate (CAGR), from $36.37M to $107.67M.
- What does EMEA — revenue mean?
- This metric represents the total gross revenue generated from product sales and service contracts within the Europe, Middle East, and Africa (EMEA) geographic region, excluding any assessed taxes. It serves as a key indicator of the company's commercial penetration and market adoption of its therapeutic portfolio in these international markets. Tracking this figure allows investors to evaluate the growth trajectory and regional performance of the company's global expansion strategy.